Now showing items 1-10 of 10

    • canSAR: an integrated cancer public translational research and drug discovery resource. 

      Halling-Brown, MD; Bulusu, KC; Patel, M; Tym, JE; Al-Lazikani, B (2012-01)
      canSAR is a fully integrated cancer research and drug discovery resource developed to utilize the growing publicly available biological annotation, chemical screening, RNA interference screening, expression, amplification ...
    • canSAR: updated cancer research and drug discovery knowledgebase. 

      Bulusu, KC; Tym, JE; Coker, EA; Schierz, AC; Al-Lazikani, B (2014-01)
      canSAR (http://cansar.icr.ac.uk) is a public integrative cancer-focused knowledgebase for the support of cancer translational research and drug discovery. Through the integration of biological, pharmacological, chemical, ...
    • ELM: the status of the 2010 eukaryotic linear motif resource. 

      Gould, CM; Diella, F; Via, A; Puntervoll, P; Gemünd, C; Chabanis-Davidson, S; Michael, S; Sayadi, A; Bryne, JC; Chica, C; Seiler, M; Davey, NE; Haslam, N; Weatheritt, RJ; Budd, A; Hughes, T; Pas, J; Rychlewski, L; Travé, G; Aasland, R; Helmer-Citterich, M; Linding, R; Gibson, TJ (2010-01)
      Linear motifs are short segments of multidomain proteins that provide regulatory functions independently of protein tertiary structure. Much of intracellular signalling passes through protein modifications at linear motifs. ...
    • Generation and characterisation of two D2A1 mammary cancer sublines to model spontaneous and experimental metastasis in a syngeneic BALB/c host. 

      Jungwirth, U; van Weverwijk, A; Melake, MJ; Chambers, AF; Gao, Q; Fivaz, M; Isacke, CM (2018-01-18)
      Studying the complex mechanisms underlying breast cancer metastasis and therapy response necessitates relevant in vivo models, particularly syngeneic models with an intact immune system. Two syngeneic spontaneously metastatic ...
    • Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. 

      Went, M; Sud, A; Speedy, H; Sunter, NJ; Försti, A; Law, PJ; Johnson, DC; Mirabella, F; Holroyd, A; Li, N; Orlando, G; Weinhold, N; van Duin, M; Chen, B; Mitchell, JS; Mansouri, L; Juliusson, G; Smedby, KE; Jayne, S; Majid, A; Dearden, C; Allsup, DJ; Bailey, JR; Pratt, G; Pepper, C; Fegan, C; Rosenquist, R; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Einsele, H; Gregory, WM; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Nickel, J; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Walker, BA; Broyl, A; Davies, FE; Hansson, M; Goldschmidt, H; Dyer, MJS; Kaiser, M; Sonneveld, P; Morgan, GJ; Hemminki, K; Nilsson, B; Catovsky, D; Allan, JM; Houlston, RS (2018-12-21)
      The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma ...
    • Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. 

      Turajlic, S; Litchfield, K; Xu, H; Rosenthal, R; McGranahan, N; Reading, JL; Wong, YNS; Rowan, A; Kanu, N; Al Bakir, M; Chambers, T; Salgado, R; Savas, P; Loi, S; Birkbak, NJ; Sansregret, L; Gore, M; Larkin, J; Quezada, SA; Swanton, C (2017-08)
      BACKGROUND: The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the ...
    • MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. 

      Missiaglia, E; Shepherd, CJ; Aladowicz, E; Olmos, D; Selfe, J; Pierron, G; Delattre, O; Walters, Z; Shipley, J (2017-01-28)
      Rhabdomyosarcomas (RMS) in children and adolescents are heterogeneous sarcomas broadly defined by skeletal muscle features and the presence/absence of PAX3/7-FOXO1 fusion genes. MicroRNAs are small non-coding RNAs that ...
    • Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. 

      Rebbeck, TR; Friebel, TM; Friedman, E; Hamann, U; Huo, D; Kwong, A; Olah, E; Olopade, OI; Solano, AR; Teo, S-H; Thomassen, M; Weitzel, JN; Chan, TL; Couch, FJ; Goldgar, DE; Kruse, TA; Palmero, EI; Park, SK; Torres, D; van Rensburg, EJ; McGuffog, L; Parsons, MT; Leslie, G; Aalfs, CM; Abugattas, J; Adlard, J; Agata, S; Aittomäki, K; Andrews, L; Andrulis, IL; Arason, A; Arnold, N; Arun, BK; Asseryanis, E; Auerbach, L; Azzollini, J; Balmaña, J; Barile, M; Barkardottir, RB; Barrowdale, D; Benitez, J; Berger, A; Berger, R; Blanco, AM; Blazer, KR; Blok, MJ; Bonadona, V; Bonanni, B; Bradbury, AR; Brewer, C; Buecher, B; Buys, SS; Caldes, T; Caliebe, A; Caligo, MA; Campbell, I; Caputo, SM; Chiquette, J; Chung, WK; Claes, KBM; Collée, JM; Cook, J; Davidson, R; de la Hoya, M; De Leeneer, K; de Pauw, A; Delnatte, C; Diez, O; Ding, YC; Ditsch, N; Domchek, SM; Dorfling, CM; Velazquez, C; Dworniczak, B; Eason, J; Easton, DF; Eeles, R; Ehrencrona, H; Ejlertsen, B; EMBRACE; Engel, C; Engert, S; Evans, DG; Faivre, L; Feliubadaló, L; Ferrer, SF; Foretova, L; Fowler, J; Frost, D; Galvão, HCR; Ganz, PA; Garber, J; Gauthier-Villars, M; Gehrig, A; GEMO Study Collaborators; Gerdes, A-M; Gesta, P; Giannini, G; Giraud, S; Glendon, G; Godwin, AK; Greene, MH; Gronwald, J; Gutierrez-Barrera, A; Hahnen, E; Hauke, J; HEBON; Henderson, A; Hentschel, J; Hogervorst, FBL; Honisch, E; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, A; Jakubowska, A; James, P; Janavicius, R; Jensen, UB; John, EM; Vijai, J; Kaczmarek, K; Karlan, BY; Kast, K; Investigators, K; Kim, S-W; Konstantopoulou, I; Korach, J; Laitman, Y; Lasa, A; Lasset, C; Lázaro, C; Lee, A; Lee, MH; Lester, J; Lesueur, F; Liljegren, A; Lindor, NM; Longy, M; Loud, JT; Lu, KH; Lubinski, J; Machackova, E; Manoukian, S; Mari, V; Martínez-Bouzas, C; Matrai, Z; Mebirouk, N; Meijers-Heijboer, HEJ; Meindl, A; Mensenkamp, AR; Mickys, U; Miller, A; Montagna, M; Moysich, KB; Mulligan, AM; Musinsky, J; Neuhausen, SL; Nevanlinna, H; Ngeow, J; Nguyen, HP; Niederacher, D; Nielsen, HR; Nielsen, FC; Nussbaum, RL; Offit, K; Öfverholm, A; Ong, K-R; Osorio, A; Papi, L; Papp, J; Pasini, B; Pedersen, IS; Peixoto, A; Peruga, N; Peterlongo, P; Pohl, E; Pradhan, N; Prajzendanc, K; Prieur, F; Pujol, P; Radice, P; Ramus, SJ; Rantala, J; Rashid, MU; Rhiem, K; Robson, M; Rodriguez, GC; Rogers, MT; Rudaitis, V; Schmidt, AY; Schmutzler, RK; Senter, L; Shah, PD; Sharma, P; Side, LE; Simard, J; Singer, CF; Skytte, A-B; Slavin, TP; Snape, K; Sobol, H; Southey, M; Steele, L; Steinemann, D; Sukiennicki, G; Sutter, C; Szabo, CI; Tan, YY; Teixeira, MR; Terry, MB; Teulé, A; Thomas, A; Thull, DL; Tischkowitz, M; Tognazzo, S; Toland, AE; Topka, S; Trainer, AH; Tung, N; van Asperen, CJ; van der Hout, AH; van der Kolk, LE; van der Luijt, RB; Van Heetvelde, M; Varesco, L; Varon-Mateeva, R; Vega, A; Villarreal-Garza, C; von Wachenfeldt, A; Walker, L; Wang-Gohrke, S; Wappenschmidt, B; Weber, BHF; Yannoukakos, D; Yoon, S-Y; Zanzottera, C; Zidan, J; Zorn, KK; Hutten Selkirk, CG; Hulick, PJ; Chenevix-Trench, G; Spurdle, AB; Antoniou, AC; Nathanson, KL (2018-05)
      The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of ...
    • The predicted impact of coding single nucleotide polymorphisms database. 

      Rudd, MF; Williams, RD; Webb, EL; Schmidt, S; Sellick, GS; Houlston, RS (2005-11)
      Nonsynonymous single nucleotide polymorphisms (nsSNP) have the potential to affect the structure or function of expressed proteins and are, therefore, likely to represent modifiers of inherited susceptibility. We have ...
    • Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer. 

      Orlando, G; Law, PJ; Cornish, AJ; Dobbins, SE; Chubb, D; Broderick, P; Litchfield, K; Hariri, F; Pastinen, T; Osborne, CS; Taipale, J; Houlston, RS (2018-10)
      Efforts are being directed to systematically analyze the non-coding regions of the genome for cancer-driving mutations1-6. cis-regulatory elements (CREs) represent a highly enriched subset of the non-coding regions of the ...